CA2307000C - Vaccins veterinaires - Google Patents

Vaccins veterinaires Download PDF

Info

Publication number
CA2307000C
CA2307000C CA2307000A CA2307000A CA2307000C CA 2307000 C CA2307000 C CA 2307000C CA 2307000 A CA2307000 A CA 2307000A CA 2307000 A CA2307000 A CA 2307000A CA 2307000 C CA2307000 C CA 2307000C
Authority
CA
Canada
Prior art keywords
vaccine
clostridium
antigens
vaccines
lambs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2307000A
Other languages
English (en)
Other versions
CA2307000A1 (fr
Inventor
Richard Buchta
Christopher Leigh Schwartzkoff
Philip Ralph Lehrbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722035.4A external-priority patent/GB9722035D0/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2307000A1 publication Critical patent/CA2307000A1/fr
Application granted granted Critical
Publication of CA2307000C publication Critical patent/CA2307000C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des vaccins vétérinaires qui sont destinés à la prévention de maladies clostridiales affectant les moutons (et agneaux) et qui assurent une immunité efficace pendant au moins un an après une seule injection ou dose.
CA2307000A 1997-10-17 1998-10-16 Vaccins veterinaires Expired - Lifetime CA2307000C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9722035.4A GB9722035D0 (en) 1997-10-17 1997-10-17 Veterinary vaccines
GB9722035.4 1997-10-17
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Publications (2)

Publication Number Publication Date
CA2307000A1 CA2307000A1 (fr) 1999-04-29
CA2307000C true CA2307000C (fr) 2011-01-04

Family

ID=25641911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2307000A Expired - Lifetime CA2307000C (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Country Status (5)

Country Link
EP (1) EP1023083A4 (fr)
AU (1) AU753804B2 (fr)
CA (1) CA2307000C (fr)
NZ (1) NZ503636A (fr)
WO (1) WO1999020305A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
AU2006324390B2 (en) * 2005-12-15 2013-08-01 Virbac (Australia) Pty Ltd A method for preventing reduced feed intake in animals and treatment of disease conditions
FR2903602B1 (fr) * 2006-07-12 2012-10-26 Seppic Sa Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
CN106177935A (zh) * 2016-08-19 2016-12-07 齐鲁动物保健品有限公司 一种反刍动物梭菌病四联灭活疫苗及其制备方法
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128325A (en) * 1964-11-11 1968-09-25 Wellcome Found Improvements in water-in-oil emulsion vaccines
US3843451A (en) * 1970-08-20 1974-10-22 Burroughs Wellcome Co Microorganism production
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2717694B1 (fr) * 1994-03-22 1996-05-03 Seppic Sa Une composition comprenant un plasmide recombinant et ses utilisations comme vaccin et médicament.
TW410158B (en) * 1995-11-30 2000-11-01 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and method for preparing same
GB9626865D0 (en) * 1996-12-24 1997-02-12 Cyanamid Websters Pty Limited Veterinary vaccines

Also Published As

Publication number Publication date
AU9616198A (en) 1999-05-10
EP1023083A1 (fr) 2000-08-02
NZ503636A (en) 2002-05-31
WO1999020305A1 (fr) 1999-04-29
EP1023083A4 (fr) 2006-06-14
WO1999020305A8 (fr) 1999-07-08
AU753804B2 (en) 2002-10-31
CA2307000A1 (fr) 1999-04-29

Similar Documents

Publication Publication Date Title
Byars et al. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity
CA2428103C (fr) Vaccins a reponse immunitaire accrue et leurs procedes de preparation
Coeshott et al. Pluronic® F127-based systemic vaccine delivery systems
AU712972B2 (en) Adjuvants for viral vaccines
EP1051189A2 (fr) Formulations de vaccin
EP0986399A1 (fr) Complexes immunostimulants chelateurs
JP2002502882A (ja) インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン
CA2307000C (fr) Vaccins veterinaires
NZ286700A (en) Vaccines comprising as an adjuvant, squalene and/or squalane, a phospholipid and a surfactant
AU626271B2 (en) Vaccine adjuvant
US3920811A (en) Adjuvant compositions
US6524592B2 (en) Veterinary vaccines
JPH08510206A (ja) サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
Tengerdy et al. Vitamin E adjuvant formulations in mice
Harrison et al. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants
CA2487968C (fr) Nouveau regime posologique de medicaments
JP3178720B2 (ja) パスツレラ・ムルトシダのトキソイドワクチン
Jones et al. Immunochemical study of antigenic specificity in delayed hypersensitivity: IV. The production of unresponsiveness to delayed hypersensitivity with a single antigenic determinant
AU776364B2 (en) Veterinary vaccines
WO1998027964A1 (fr) Vaccins a usage veterinaire
Nauciel Delayed hypersensitivity to azobenzenearsonate amino acids conjugates. In vitro study of the specificity of the immune response by 3H-thymidine incorporation into lymph node cells
Woodhour et al. Development and Application of New Parenteral Adjuvants: V. Comparative Potencies of Influenza Vaccines Emulsified in Various Oils
Wardlaw et al. Loss of adjuvanticity in rats for the hyperacute form of allergic encephalomyelitis and for reaginic antibody production in mice of a phenotypic variant of Bordetella pertussis.
Dias et al. Vitamin A as adjuvant to the mouse immune response to pertussis, tetanus and diphtheria vaccines
Stewart-Tull The future potential for the use of adjuvants in human vaccines

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181016